A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 317
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AA
Long Form : anaplastic astrocytoma
No. Year Title Co-occurring Abbreviation
2020 A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. AO, DC, GBM
2020 Anaplastic Astrocytoma: State of the art and future directions. ---
2020 Autophagy as a Potential Therapy for Malignant Glioma. GBM
2020 Coumarins modulate the anti-glioma properties of temozolomide. GBM
2020 Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications. DA, GBM, GEP
2020 Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET. FET, GBM, IDH, MGMT, MTV, PFS, OS, TTP, WHO
2020 Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. DCE, DSC, EF, FLAIR, IRB, PFS, RANO, SI
2019 Association between medical academic genealogy and publication outcome: impact of unconscious bias on scientific objectivity. GTR, HGG, OR
2019 c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. DA
10  2019 Clinical Significance of Molecular Diagnosis of Pilocytic Astrocytoma: A Case Report. DA, PA
11  2019 Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database. DA, DA, GTR, HR, mIDH, SEER
12  2019 Serum miR-29b as a novel biomarker for glioblastoma diagnosis and prognosis. GBM, miRNA, qRT-PCR, ROC
13  2019 The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. GBM, mOS
14  2018 Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? BEV, FSRT, GBM, HGG, MST, OS
15  2018 IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. GBMs
16  2018 Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection. GB, GTR, STR
17  2018 p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors. CNS, DA, GB
18  2018 The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma. BEV, GBM, OS, TMZ
19  2018 Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. AO, AOA, EOR, IDH1, OS
20  2018 Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). GBM, HGG, OS, TMZ
21  2018 Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report. FET, IVF
22  2017 Differential diagnosis of posterior fossa brain tumors: Multiple discriminant analysis of Tl-SPECT and FDG-PET. FDG, GBM, HB, LGG, MB, mets, ML, Tl
23  2017 High ATP2A2 expression correlates with better prognosis of diffuse astrocytic tumor patients. DA
24  2017 IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over. DA, GBM, IHC, WHO
25  2017 Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. OS
26  2017 Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. HR, NU, OS, PFS, RT, TMZ, TTP
27  2017 Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. GBM, NeoTMZ, PS, RT, TMZ
28  2017 Prognostic value of survivin and DNA topoisomerase IIalpha in diffuse and anaplastic astrocytomas. DA, Ki67, TIIalpha
29  2017 Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in children with brain tumors. bFGF, GBM, VEGF
30  2017 The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. GBMs, ODGs, OS, TERTp, WT
31  2017 The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ---
32  2017 [Clinical effects of microsurgery in spinal cord anaplastic astrocytoma]. ---
33  2016 Anaplastic astrocytoma. TMZ
34  2016 Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. NCDB, OS, RT
35  2016 Epidermal growth factor receptor (EGFR) gene amplification in high-grade gliomas: Western Indian tertiary cancer center experience. AO, AOA, EGFR, GBMO, HGGs
36  2016 Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma. DA, DIA, GBM, MnSOD, OS, PFS
37  2016 miRNA regulation of Sirtuin-1 expression in human astrocytoma. GBM, LGA, NBT, PAAC, PGBMC, primary LGA cells, RT-qPCR, Sirt-1
38  2016 Network analysis of microRNAs, transcription factors, target genes and host genes in human anaplastic astrocytoma. miRNAs, TFs
39  2016 Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. EFS, GBM, MGMT
40  2016 Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach. AO, AOA, ATRX, FFPE, OS, RFS
41  2016 Rapid increase in cystic volume of an anaplastic astrocytoma misdiagnosed as neurocysticercosis: A case report. MRI
42  2015 Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. PFS, RT, TMZ
43  2015 An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals. DA, GBM, KEGG, PAM
44  2015 Analysis of survival in pediatric high-grade brainstem gliomas: A population-based study. CIs, GBM, HR, SEER
45  2015 Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. HGG
46  2015 Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. POF, RANO-F
47  2015 Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. HR, TTP
48  2015 Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. KPS, OS
49  2015 Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. GBM, IDH, OS
50  2015 Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. AO, AOA, OS, PFS, RT
51  2015 Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. GBM, OS, RIT, RPA
52  2015 Nuclear Localization Signal-Enhanced Polyurethane-Short Branch Polyethylenimine-Mediated Delivery of Let-7a Inhibited Cancer Stem-Like Properties by Targeting the 3'-UTR of HMGA2 in Anaplastic Astrocytoma. CSCs, miRNA, NLS, PU-PEI
53  2015 Profile of nimotuzumab in the treatment of high-grade glioma. DIPG, EGFR, GBM, HGG
54  2015 Radiotherapy and temozolomide for anaplastic astrocytic gliomas. AOA, RA
55  2015 Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. PFS
56  2015 Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas. CR, GBM, IMRT, KPS, MRI, PR, re-RT, RT, SD
57  2014 A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. EMT, GBM, PAM
58  2014 Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. AO, AOA, EORTC, IDH, OS, PCV, RCTs, RT, RTOG
59  2014 Anaplastic astrocytomas: survival and prognostic factors in a surgical series. OS
60  2014 Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination. TMZ
61  2014 Effectiveness of radiotherapy for elderly patients with anaplastic gliomas. AO, CI, GTR, HR, RT
62  2014 IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. IDH1, MGMT, RT, TMZ
63  2014 Incidence and relative survival of anaplastic astrocytomas. ---
64  2014 Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care study. GBM
65  2014 Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. GBM
66  2014 Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. GBM, HGG, PFS, RT
67  2014 Survival of patients treated with radiation therapy for anaplastic astrocytoma. RT, RTOG-RPA
68  2014 The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. AO, AOA, GBM, OS, RT, SEER
69  2014 The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. IDH, RT, TMZ
70  2014 [Differential diagnosis of brain gliomas by positron emission tomography using various radiopharmaceuticals]. 11C-COL, 11C-MET, 11C-SB, 18F-FDG, AI, BA, BG, GBM, PET, TRPs
71  2014 [Preliminary clinical evaluations of bevacizumab for recurrent malignant glioma in Chinese patients]. BEV, GBM, HGG, OS, PFS
72  2013 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. AO, AOA, OS, PFS
73  2013 Anaplastic astrocytoma. AED, GB, LMWH, MG, RT, TMZ, VTE
74  2013 Anaplastic astrocytomas with abundant Rosenthal fibers in elderly patients: a diagnostic pitfall of high-grade gliomas. IDH1, RFs
75  2013 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. ALT, AO, AOA, ATRX, IDH, MGMT
76  2013 CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas. DA, DFS, GBM, PA, PI, RG
77  2013 Cerebellar anaplastic astrocytoma in an adult with neurofibromatosis type 1: case report and review of literature. ALA, MGMT, MRI, NF1
78  2013 Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. GBM, OS, PFS, TMZ
79  2013 Glioma infiltration of the corpus callosum: early signs detected by DTI. ADC, CC, DTI, FA, GBM
80  2013 Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. pGBM
81  2013 Intensity-modulated fractionated stereotactic radiotherapy with reduced margin for high grade gliomas: dosimetric analysis of sparing optic nerve & chiasm. GBM, IM-FSRT
82  2013 Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. CRT, OS, PFS, RT, RT-C
83  2013 Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). ACNU, GBM, MGMT, OS, PCZ, PFS
84  2013 Survival and prognostic factors of anaplastic gliomas. AO, HR
85  2013 Telomere length modulation in human astroglial brain tumors. GBM, LGA, NBT, TANKs-PARP, TRAP, TRF
86  2013 The prognosis of anaplastic astrocytoma with radiologic necrosis mimicking glioblastoma. OS, PFS, RTOG-RPA
87  2013 Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. EGFR, GBM, mTBF, pCASL, ROC, ROIs
88  2013 [A molecular classification system for anaplastic glioma]. AO, AOA, MGMT, OS, PFS, PFs
89  2013 [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. CR, GBM, GD-MRI, ITT, PD, PFS, PR, SD, TMZ
90  2012 A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. GB
91  2012 Anaplastic glioma. AE, AG, AO, AOA, RT, TMZ
92  2012 Cathepsin D and its prognostic value in neuroepithelial brain tumors. Cath D, DA, GB, MB
93  2012 Differential expression of a novel voltage gated potassium channel--Kv 1.5 in astrocytomas and its impact on prognosis in glioblastoma. DA, GBM, LI
94  2012 Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. ConcT with TMZ, KPS, RT
95  2012 Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. DA, GBM
96  2012 IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. DA, GBM, WHO
97  2012 Long term experience in high grade glial tumors with temozolomide. CRs, GBM, HGGs, ORR, OS, PFS, PRs, RT
98  2012 Nix protein positively regulates NF-kappaB activation in gliomas. AS, EMSA, GBM, NF-kappaB
99  2012 Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. GB, LI
100  2012 Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. CTCAE, DLT, MTD, RT, SRS